Crossmark

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Crossref DOI link: https://doi.org/10.1186/s40425-018-0489-5

Published Online: 2019-01-24

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Conroy, Jeffrey M.

Pabla, Sarabjot

Nesline, Mary K.

Glenn, Sean T.

Papanicolau-Sengos, Antonios

Burgher, Blake

Andreas, Jonathan

Giamo, Vincent

Wang, Yirong

Lenzo, Felicia L.

Bshara, Wiam

Khalil, Maya

Dy, Grace K.

Madden, Katherine G.

Shirai, Keisuke

Dragnev, Konstantin

Tafe, Laura J.

Zhu, Jason

Labriola, Matthew

Marin, Daniele

McCall, Shannon J.

Clarke, Jeffrey

George, Daniel J.

Zhang, Tian

Zibelman, Matthew

Ghatalia, Pooja

Araujo-Fernandez, Isabel

de la Cruz-Merino, Luis

Singavi, Arun

George, Ben

MacKinnon, Alexander C.

Thompson, Jonathan

Singh, Rajbir

Jacob, Robin

Kasuganti, Deepa

Shah, Neel

Day, Roger

Galluzzi, Lorenzo

Gardner, Mark

Morrison, Carl https://orcid.org/0000-0002-3441-8363
More Information

Article History

Received: 6 September 2018

Accepted: 19 December 2018

First Online: 24 January 2019

Ethics approval and consent to participate

: Existing deidentified specimens and associated clinical data was submitted to OmniSeq from Roswell Park Comprehensive Cancer Center (Buffalo, NY), Fox Chase Cancer Center (Philadelphia, PA), Duke University Medical Center (Durham, North Carolina), Dartmouth-Hitchcock Medical Center (Lebanon, NH), Medical College of Wisconsin (Milwaukee, WI), Meharry Medical College (Nashville, Tennessee), Northwest Oncology (Munster, IN), and Hospital Universitario Virgen Macarena (Sevilla, Spain) with institutional review board approval from each individual institution. OmniSeq’s analysis utilized deidentified data that was considered non-human subjects research under IRB-approved protocol (BDR #080316) at Roswell Park Comprehensive Cancer Center (Buffalo, NY).

: Not applicable.

: Disclosures: KGM, KS, KD, LJT, JZ, ML, DM, SJM, JMC, DJG, TZ, MZ, PG, IAF, LdlCM, AS, BG, AM, JT, RS, RJ, DH, NS and RD have no conflicts of interest to disclose. JMC, SP, MN, STG, APS, BB, JA, VG, YW, FLL, MG and CM are all employees of OmniSeq, Inc. (Buffalo, NY) and hold restricted stock in OmniSeq, Inc. MK, GD, WB, CM, STG, and JMC are employees of Roswell Park Comprehensive Cancer Center (Buffalo, NY). Roswell Park Comprehensive Cancer Center is the majority shareholder of OmniSeq, Inc. LG provide remunerated consulting to OmniSeq, Inc.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below